Cyclic Isothiourea CXCR4 Modulators Targeting Minor Pocket
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CXCR4 antagonists are ineffective in inhibiting inflammatory cytokine production while minimizing impact on the CXCR4-CXCL12 signaling pathway, posing a risk of toxicity and adverse effects in long-term use for treating inflammatory, autoimmune, and autoinflammatory disorders.
Innovation Solution
Development of novel compounds targeting the CXCR4 minor pocket, specifically inhibiting interferon and inflammatory cytokine production with minimal disruption to the CXCR4-CXCL12 signaling pathway, as exemplified by compounds of formula (I), which are designed to treat inflammatory, autoimmune, and autoinflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CXCR4 antagonists are used to treat inflammatory disorders, then inflammatory cytokine production is inhibited, but the CXCR4-CXCL12 signaling pathway is disrupted causing toxicity and adverse effects
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target the minor pocket of CXCR4 receptor, producing a localized therapeutic effect on inflammatory cytokine production while leaving the major pocket-mediated CXCR4-CXCL12 signaling pathway intact. This spatially differentiated binding approach enables inhibition of pathogenic cytokines without disrupting essential physiological signaling, thereby resolving the contradiction between therapeutic efficacy and safety.
2Productivity
If CXCR4 antagonists are used to inhibit inflammatory cytokine production, then therapeutic effect is achieved, but long-term use causes toxicity
Solution Approach 1:
The patent segments the CXCR4 receptor binding site into two distinct pockets: the major pocket (involved in CXCR4-CXCL12 signaling) and the minor pocket (involved in inflammatory cytokine regulation). By designing compounds that specifically target only the minor pocket, the invention achieves segmentation of therapeutic action, enabling long-term use to inhibit inflammatory cytokines without causing the toxicity associated with broad CXCR4 antagonism.
3Object-generated harmful factors
If broad CXCR4 inhibition is applied, then inflammatory cytokine production is suppressed, but the CXCR4-CXCL12 signaling pathway is affected
Solution Approach 1:
The patent introduces a selective molecular intermediary that binds specifically to the minor pocket of CXCR4, acting as a mediator between therapeutic intervention and cytokine suppression. This intermediary compound (formula I) transmits the inhibitory effect to inflammatory cytokine production pathways while physically and functionally isolating the major pocket-mediated CXCR4-CXCL12 signaling pathway from disruption, thereby maintaining signaling integrity during long-term therapy.
Data Source
AI summary
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.